Nouvelle déclaration d'incident
No de la demande: 2019-2340
Numéro de référence du titulaire d'homologation: USA-BAYERBAH-2019-US0016593 (Report 558424)
Nom du titulaire (nom légal complet, aucune abbréviation): Bayer inc
Adresse: 2920 Matheson Blvd
Ville: Mississaugua
État: ON
Pays: Canada
Code postal /Zip: L4W 5R6
Incident chez un animal domestique
Pays: UNITED STATES
État: MICHIGAN
Inconnu
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 11556-127
Nom du produit: Advantage Plus Spot-on 2.5 ml (250 mg Imi / 12.5 mg Pyri) Dog > 10-25
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Seresto Large Dog collar
Autre (préciser)
spot onOui
Unités: mL
Site: Animal / Usage sur un animal domestique
Inconnu
Propriétaire de l'animal
Dog / Chien
Australian Shepherd Dog
1
Homme
17
Inconnu
Cutanée
Unknown / Inconnu
Unknown / Inconnu
Système
Unknown / Inconnu
Inconnu
Inconnu
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On an unspecified date in approximately 2018, post product application, the dog exhibited ataxia and a stiff gait and the collar was removed. On an unspecified date in approximately 2018, approximately 3 days post collar removal, the clinical signs resolved. On an unspecified date in approximately 2018, the dog died. No Necropsy was performed. Due to the sensitive nature of the communication, specific relevant details were not obtained, nor will they be sought. The intent of the call was to inquire about product use in general and not to report this event.
Mort
Sereso: O - Unclassifiable/unassessable Stiff gait is not expected after appropriate topical product application as inconsistant with products pharmaco-toxicological profile. Ataxia is not typically seen with appropriate topical product administration. Even with oral product exposure which was not reported only transient gastrointestinal signs are expected. Time to onset is unknown. Further, death is not expected following appropriate topical product application as inconsistent with product's pharmacological profile. Moreover it was reported after collar removal. Oral exposure to the collar is not expected to cause serious signs either. An overdose of 5 collars around the neck was investigated in adult cats and dogs for an 8 months period and in 10 week old kittens and 7 week old puppies for a 6 months period without causing serious signs. Other causes are more likely in this geriatric dog of 17 years. Moreover the intent of the call was to inquire about product use in general and not to report this event. In summary, based on the provided information, product relation remains unassessable. Advantage: O - Unclassifiable/unassessable Stiff gait is not expected after appropriate topical product application as inconsistent with products pharmaco-toxicological profile. Ataxia is not typically observed with appropriate topical product administration. Death is inconsistent with pharmaco-toxicological product profile and experience. Product has wide margin of safety. The oral LD50 in rat is 642 mg/kg BW. 20-fold overdosage tolerated by dogs without showing any side effect. Other causes are more likely in this geriatric dog of 17 years. Moreover the intent of the call was to inquire about product use in general and not to report this event. Time to onset is unknown. Considering all aspects, product relation is unassessable.